|
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
<b>Conclusion:</b><i>CYP2D6*10</i> pharmacogenetic-guided selective estrogen receptor modulator can be a cost-effective strategy in the Chinese patients with hormone receptor-positive breast cancer.
|
31769341 |
2020 |
|
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
Our aim was to quantify mediating effects of fasting insulin and free estradiol in the adiposity and ER-positive postmenopausal breast cancer association.
|
31187481 |
2020 |
|
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
We conducted a case-control study (4,059 cases and 4,059 matched controls) nested within the E3N French cohort study to estimate the risk of breast cancer associated with long-term exposure to airborne cadmium pollution, and its effect according to molecular subtype of breast cancer (estrogen receptor negative/positive [ER-/ER+] and progesterone receptor negative/positive [PR-/PR+]).
|
30851122 |
2020 |
|
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
The clinical efficacy of new HER2-targeting antibody-drug conjugates needs to be validated in this high-risk subset of ER+ breast cancer patients.
|
31811505 |
2020 |
|
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
Breast cancer (BC) is the most common cancer in women, where hormone receptor-positive (HR+; estrogen receptor and/or progesterone receptor) BC comprises the majority (>50%) and has better prognosis, while a minority (<20%) are triple negative BC (TNBC), which has an aggressive phenotype.
|
31502168 |
2020 |
|
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
Patients with estrogen receptor-expressing early-stage operable breast cancer who received depomedroxyprogesterone acetate for hot flashes between January 2005 and December 2012 were identified.
|
31402403 |
2020 |
|
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
Combination with BRAF/MEK pathway activities could improve ER status-based recurrence prediction for breast cancer.
|
31547956 |
2020 |
|
Malignant neoplasm of breast
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy.
|
31562570 |
2020 |
|
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
We aimed to compare stemness profile of two major subtypes [Estrogen receptor positive (ER<sup>+</sup>) and negative (ER<sup>-</sup>)] breast cancer using different sets of markers.
|
30361903 |
2020 |
|
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
More than 75% of breast cancers are estrogen receptor alpha (ERα) positive (ER+), and resistance to current hormone therapies occurs in one-third of ER+ patients.
|
31721572 |
2020 |
|
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
Most importantly, high HMGA1 predicted decreased overall survival (P < 0.0001) for all women with breast cancer and further stratified ER-positive tumors into those with inferior outcomes.
|
31531802 |
2020 |
|
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
With the advent of omic technologies, our understanding of the molecular mechanisms underlying estrogen receptor α (ERα)-expressing breast cancer (BC) progression has grown exponentially.
|
30389467 |
2019 |
|
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
The positive association of postmenopausal BC risk and specifically estrogen receptor (ER)-positive BC, is presumably due largely to accumulation of estrogen in the adipose tissue of the breast and other tissues.
|
31555578 |
2019 |
|
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
ESR1 mutations: a new biomarker in breast cancer.
|
31188645 |
2019 |
|
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
Estrogens are key factors in the development of the estrogen receptor-positive (ER<sup>+</sup>) breast cancer.
|
31440781 |
2019 |
|
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
VULCAN analysis of estrogen receptor activation in breast cancer highlights the key components of the estrogen receptor complex alongside a novel interaction with GRHL2.
|
31084623 |
2019 |
|
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
Likewise, resistance to endocrine therapy remains the major challenge in the management of patients with ER + ve BC.
|
31336602 |
2019 |
|
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
Current standard-of-care (SOC) therapy for breast cancer includes targeted therapies such as endocrine therapy for estrogen receptor-alpha (ERα) positive; anti-HER2 monoclonal antibodies for human epidermal growth factor receptor-2 (HER2)-enriched; and general chemotherapy for triple negative breast cancer (TNBC) subtypes.
|
30691108 |
2019 |
|
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
Three of these, TDRD10, PRAC2 and TMEM132C, contained CpG sites that showed diagnostic and prognostic value in breast cancer, particularly in estrogen-receptor (ER)-positive samples.
|
30866861 |
2019 |
|
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
The aim of the current study was to examine the effects of treatment with combined doses of bac I and bac II using four cell lines representative of the breast cancer subtypes: triple negative (MDA-MB-231), estrogen receptor positive (T47D and MCF7) and human epidermal growth factor receptor 2 (HER2) positive (BT-474).
|
31574930 |
2019 |
|
Malignant neoplasm of breast
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
Despite clinical efficacy, these interventions have limitations, including rare but serious side effects and lack of activity against estrogen receptor-negative breast cancers.
|
30720225 |
2019 |
|
Malignant neoplasm of breast
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
In our binary regression model, breast cancer patients with rosacea had a higher prevalence of estrogen receptor-positive status, lower high-density lipoprotein levels and higher low-density lipoprotein than patients with breast cancer but no rosacea.
|
31120152 |
2019 |
|
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
Very interestingly, NMK-T-057 was found to inhibit proliferation, colony-forming ability, and motility in various breast cancer (BC) cells such as MDA-MB-231, MDA-MB-468, 4T1 (triple-negative cells), and MCF-7 (estrogen receptor (ER)/progesterone receptor (PR)-positive cell line) with negligible cytotoxicity against noncancerous cells (MCF-10A and peripheral blood mononuclear cells).
|
30824542 |
2019 |
|
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
The prevalence of triple-negative and hormone receptor-negative breast cancer (negative for estrogen receptor and progesterone receptor) among each group of foreign-born black women was compared with that among US-born black women and was expressed as the adjusted prevalence rate ratio, accounting for sociodemographic and tumor characteristics.
|
31190337 |
2019 |
|
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
<b>Principal conclusions:</b> Tumor-associated MUC1 is a very important biomarker for breast cancer next to the traditional markers estrogen receptor (ER), progesterone receptor (PR) and HER/2-neu.
|
31588183 |
2019 |